1111 Targeting lipid metabolism to improve PARP inhibitor response in BRCA-associated TNBC

1111 Targeting lipid metabolism to improve PARP inhibitor response in BRCA-associated TNBC

Bibliographic Details
Main Authors:	Geoffrey I Shapiro, Jessica Thaxton, Anita Mehta, Jennifer L Guerriero, Adam Nelson, Carlos Wagner Wanderley, Filipa Lynce, Madeline G Townsend, Kelly F Zheng, Daniel E Michaud, Kiran Kurmi, Shakchhi Joshi, Marcia Haigis
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2023-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

614 Investigating immune mediated mechanisms of PARPi resistance in BRCA1-associated triple negative breast cancer (TNBC)
by: Elizabeth Mittendorf, et al.
Published: (2021-11-01)

982 Immune mediated mechanisms of PARPi resistance in BRCA1-associated triple negative breast cancer (TNBC)
by: Geoffrey I Shapiro, et al.
Published: (2023-11-01)

DAXX, as a Tumor Suppressor, Impacts DNA Damage Repair and Sensitizes BRCA-Proficient TNBC Cells to PARP Inhibitors
by: Yaqin Shi, et al.
Published: (2019-06-01)

OGG1 Inhibition Triggers Synthetic Lethality and Enhances The Effect of PARP Inhibitor Olaparib in BRCA1-Deficient TNBC Cells
by: Juan Miguel Baquero, et al.
Published: (2022-05-01)

Cdh1 Deficiency Sensitizes TNBC Cells to PARP Inhibitors
by: Junjun Li, et al.
Published: (2022-04-01)

Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance
by: Desh Deepak Singh, et al.
Published: (2021-10-01)

STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA-associated breast cancer
by: Constantia Pantelidou, et al.
Published: (2022-09-01)

Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies
by: Marilyne Labrie, et al.
Published: (2021-10-01)

The "11.11" phenomenon in China
by: Chen, Lu (Lu Alora)
Published: (2016)

A BRCA2 germline mutation and high expression of immune checkpoints in a TNBC patient
by: Yuyi Han, et al.
Published: (2023-10-01)

PARP Inhibitors in the Management of BRCA-Positive Prostate Cancer: An Overview
by: Islam Kourampi, et al.
Published: (2023-01-01)

Oxaliplatin prior to PARP inhibitor in BRCA-mutated ovarian cancer
by: Maria Ornella Nicoletto, et al.
Published: (2023-06-01)

TRIM21 mediates the synergistic effect of Olaparib and Sorafenib by degrading BRCA1 through ubiquitination in TNBC
by: Ning Huang, et al.
Published: (2023-10-01)

Beyond breast and ovarian cancers: PARP inhibitors for BRCA mutation-associated and BRCA-like solid tumors
by: Ciara C. O'Sullivan, et al.
Published: (2014-02-01)

Total synthesis of (+)-11,11′-dideoxyverticillin A
by: Kim, Justin, et al.
Published: (2018)

Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status
by: Man Yee Keung, et al.
Published: (2020-03-01)

The pro- and anti-tumor roles of mesenchymal stem cells toward BRCA1-IRIS-overexpressing TNBC cells
by: Daniel Ryan, et al.
Published: (2019-04-01)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
by: Shicheng Yang, et al.
Published: (2023-05-01)

A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers
by: Tingting Du, et al.
Published: (2022-07-01)

PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting
by: Karolina N. Dziadkowiec, et al.
Published: (2017-02-01)

Consolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide
by: Yosuke Hirotsu, et al.
Published: (2020-05-01)

BRCA1 Versus BRCA2 and PARP Inhibitors Efficacy in Solid Tumors:A Meta-Analysis of Randomized Controlled Trials
by: Shan Li, et al.
Published: (2021-10-01)

P11.11 SYSTEMIC LUPUS ERYTHEMATOSUS AND CARDIOVASCULAR EVENTS
by: A. Cypiene, et al.
Published: (2011-11-01)

BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors
by: Reisländer, T, et al.
Published: (2019)

Chlorambucil targets BRCA1/2‐deficient tumours and counteracts PARP inhibitor resistance
by: Tacconi, E, et al.
Published: (2019)

Abrogation of KLF5 sensitizes BRCA1-proficient pancreatic cancer to PARP inhibition
by: Zhang Zheng, et al.
Published: (2024-03-01)

Chlorambucil targets BRCA1/2‐deficient tumours and counteracts PARP inhibitor resistance
by: Eliana MC Tacconi, et al.
Published: (2019-07-01)

Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition
by: Diar Aziz, et al.
Published: (2021-08-01)

Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic Approaches
by: Sayra Dilmac, et al.
Published: (2023-07-01)

PARP Inhibitors for Breast Cancer: Germline <em>BRCA1/2</em> and Beyond
by: Maria Clara Saad Menezes, et al.
Published: (2022-09-01)

In Silico Investigation of the Molecular Mechanism of PARP1 Inhibition for the Treatment of BRCA-Deficient Cancers
by: Fengqin Yan, et al.
Published: (2023-02-01)

Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors
by: Isabella Faraoni, et al.
Published: (2018-12-01)

Prospects of PARP Inhibitors in Treatment of BRCA-Mutated Pancreatic Cancer: a Literature Review
by: K. V. Menshikov, et al.
Published: (2022-06-01)

Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors
by: Yu-Yi Chu, et al.
Published: (2022-10-01)

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
by: Colombo I, et al.
Published: (2018-03-01)

PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors
by: Anna D. Staniszewska, et al.
Published: (2022-12-01)

PARP Inhibition by Flavonoids Induced Selective Cell Killing to BRCA2-Deficient Cells
by: Cathy Su, et al.
Published: (2017-10-01)

BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors
by: Timo Reisländer, et al.
Published: (2019-07-01)

Macrophage Biology and Mechanisms of Immune Suppression in Breast Cancer
by: Anita K. Mehta, et al.
Published: (2021-04-01)

The Landscape of Targeted Therapies in TNBC
by: Elena Vagia, et al.
Published: (2020-04-01)